Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescent analysis of CD24 (green) showing staining in the cytoplasm of NIH-3T3 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a CD24 monoclonal antibody (Product # MA5-11828) in 3% BSA-PBS at a dilution of 1:20 and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a flourescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Cell membrane antigen preparation isolated from NALM-1 human pre-B leukemia cell line|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay Dependent|
|Immunohistochemistry (Frozen) (IHC (F))||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-11828 targets CD24 in FACS, IHC (F), ICC/IF and WB applications and shows reactivity with Human and Mouse samples. This antibody detects a few non-specific bands in BAF-3 cell lysates.
The MA5-11828 immunogen is cell membrane antigen preparation isolated from NALM-1 human pre-B leukemia cell line.
CD24 is a two-chain glycosylphosphatidylinositol (GPI)-anchored glycoprotein expressed at multiple stages of B-cell development, beginning with the bone marrow pro-B-cell compartment and continuing through mature, surface Ig positive B-cells. Plasma cell expression is very low or negative. It is also expressed on the majority of B-lineage acute lymphoblastic leukemias, B-cell CCLs and B-cell non-Hodgkin's lymphomas. CD24 may play a role in regulation of B-cell proliferation and maturation.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
MA5-11828 was used in immunohistochemistry to evaluate the expression of CD24, CD44, CD133 and ALDH1 in invasive ductal carcinoma of the breast
|Kapucuoğlu N,Bozkurt KK,Başpınar Ş,Koçer M,Eroğlu HE,Akdeniz R,Akçil M||Pathology, research and practice (211:740)||2015|
Fibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotype.
MA5-11828 was used in immunohistochemistry to study the claudin expression in fibromatosis-like metaplastic carcinoma of the breast
|Rito M,Schmitt F,Pinto AE,André S||Virchows Archiv : an international journal of pathology (465:185)||2014|
CD24 and CD44 in salivary gland pleomorphic adenoma and in human salivary gland morphogenesis: differential markers of glandular structure or stem cell indicators?
MA5-11828 was used in immunohistochemistry to study whether CD24 and CD44 expression in salivary glands can be used as markers of cancer stem cells
|Ianez RC,Coutinho-Camillo CM,Buim ME,Pinto CA,Soares FA,Lourenço SV||Histopathology (62:1075)||2013|
Acetaminophen-induced differentiation of human breast cancer stem cells and inhibition of tumor xenograft growth in mice.
MA5-11828 was used in immunohistochemistry to screen compounds able to induce differentiation of cancer stem cells
|Takehara M,Hoshino T,Namba T,Yamakawa N,Mizushima T||Biochemical pharmacology (81:1124)||2011|
Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status.
MA5-11828 was used in immunohistochemistry to study the clinical significance of CD24 and CD44 expression in breast cancer.
|Kim HJ,Kim MJ,Ahn SH,Son BH,Kim SB,Ahn JH,Noh WC,Gong G||Breast (Edinburgh, Scotland) (20:78)||2011|
CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery.
MA5-11828 was used in immunohistochemistry to study the role of CD24 in tumor invasion and its prognostic significance in hepatocellular carcinoma
|Yang XR,Xu Y,Yu B,Zhou J,Li JC,Qiu SJ,Shi YH,Wang XY,Dai Z,Shi GM,Wu B,Wu LM,Yang GH,Zhang BH,Qin WX,Fan J||Clinical cancer research : an official journal of the American Association for Cancer Research (15:5518)||2009|
Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
MA5-11828 was used in immunohistochemistry to study whether cancer stem cells are clinically significant for resistance to chemotherapy in human breast cancers
|Tanei T,Morimoto K,Shimazu K,Kim SJ,Tanji Y,Taguchi T,Tamaki Y,Noguchi S||Clinical cancer research : an official journal of the American Association for Cancer Research (15:4234)||2009|
Laser capture microdissection-microarray analysis of focal segmental glomerulosclerosis glomeruli.
MA5-11828 was used in immunohistochemistry to analyse the focal segmental glomerulosclerosis glomeruli by laser capture microdissection-microarray method
|Bennett MR,Czech KA,Arend LJ,Witte DP,Devarajan P,Potter SS||Nephron. Experimental nephrology (107:e30)||2007|
CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma.
MA5-11828 was used in immunohistochemistry to study CD24 expression as a prognostic factor in intrahepatic cholangiocarcinoma
|Su MC,Hsu C,Kao HL,Jeng YM||Cancer letters (235:34)||2006|
Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival.
MA5-11828 was used in immunohistochemistry to study the prognostic value of cytoplasmic CD24 expression in colorectal cancer
|Weichert W,Denkert C,Burkhardt M,Gansukh T,Bellach J,Altevogt P,Dietel M,Kristiansen G||Clinical cancer research : an official journal of the American Association for Cancer Research (11:6574)||2005|
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
MA5-11828 was used in immunohistochemistry to distinguish low malignant potential serous ovarian carcinomas from invasive counterparts
|Meinhold-Heerlein I,Bauerschlag D,Hilpert F,Dimitrov P,Sapinoso LM,Orlowska-Volk M,Bauknecht T,Park TW,Jonat W,Jacobsen A,Sehouli J,Luttges J,Krajewski M,Krajewski S,Reed JC,Arnold N,Hampton GM||Oncogene (24:1053)||2005|
Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
MA5-11828 was used in immunohistochemistry to profile the expression patterns of microdissected prostate cancer samples to identify new prognostic markers
|Kristiansen G,Pilarsky C,Wissmann C,Kaiser S,Bruemmendorf T,Roepcke S,Dahl E,Hinzmann B,Specht T,Pervan J,Stephan C,Loening S,Dietel M,Rosenthal A||The Journal of pathology (205:359)||2005|
CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer.
MA5-11828 was used in immunohistochemistry to study the prognostic value of CD24 expression in low grade or organ confined prostate cancer
|Kristiansen G,Pilarsky C,Pervan J,Stürzebecher B,Stephan C,Jung K,Loening S,Rosenthal A,Dietel M||The Prostate (58:183)||2004|
Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus.
MA5-11828 was used in flow cytometry to examine the antibody repertoire of patients with acute systemic lupus erythematosus.
|Tipton CM,Fucile CF,Darce J,Chida A,Ichikawa T,Gregoretti I,Schieferl S,Hom J,Jenks S,Feldman RJ,Mehr R,Wei C,Lee FE,Cheung WC,Rosenberg AF,Sanz I||Nature immunology (16:755)||2015|
CD24 expression as a marker for predicting clinical outcome in human gliomas.
MA5-11828 was used in western blot to study the prognostic value of CD24 expression in human gliomas
|Deng J,Gao G,Wang L,Wang T,Yu J,Zhao Z||Journal of biomedicine & biotechnology (2012:null)||2012|
CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma.
MA5-11828 was used in western blot to study the prognostic value of CD24 overexpression in esophageal squamous cell carcinoma
|Sano A,Kato H,Sakurai S,Sakai M,Tanaka N,Inose T,Saito K,Sohda M,Nakajima M,Nakajima T,Kuwano H||Annals of surgical oncology (16:506)||2009|
The role of extracellular factors in human metastatic chordoma cell growth in vitro.
MA5-11828 was used in western blot to study the role of the extracellular microenvironment in human metastatic chordoma cell growth in vitro
|Ostroumov E,Hunter CJ||Spine (32:2957)||2007|
CD24 antigen (small cell lung carcinoma cluster 4 antigen); CD24A; cluster of differentiation 24; FLJ22950; FLJ43543; heat stable antigen; lymphocyte antigen 52; M1/69-J11D heat stable antigen; MGC75043; R13-Ag; signal transducer CD24; X62 heat stable antigen
CD24; CD24A; HSA; Ly-52; nectadrin